Westfield Capital Management Co. LP Acquires 214,795 Shares of Masimo Co. (NASDAQ:MASI)

Westfield Capital Management Co. LP lifted its holdings in shares of Masimo Co. (NASDAQ:MASIFree Report) by 35.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 818,476 shares of the medical equipment provider’s stock after purchasing an additional 214,795 shares during the period. Westfield Capital Management Co. LP owned about 1.55% of Masimo worth $95,934,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Neuberger Berman Group LLC bought a new position in shares of Masimo during the 4th quarter valued at $505,000. Commerce Bank grew its holdings in Masimo by 60.4% in the 4th quarter. Commerce Bank now owns 4,085 shares of the medical equipment provider’s stock worth $479,000 after acquiring an additional 1,539 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Masimo by 851.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 264 shares during the last quarter. Corient Private Wealth LLC grew its holdings in Masimo by 66.4% in the 4th quarter. Corient Private Wealth LLC now owns 4,037 shares of the medical equipment provider’s stock worth $473,000 after acquiring an additional 1,611 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Masimo by 282.0% in the 4th quarter. Wells Fargo & Company MN now owns 116,712 shares of the medical equipment provider’s stock worth $13,680,000 after acquiring an additional 86,162 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Stock Up 1.8 %

NASDAQ MASI traded up $2.25 during trading hours on Friday, reaching $127.00. 606,517 shares of the company’s stock traded hands, compared to its average volume of 823,578. Masimo Co. has a 52-week low of $75.22 and a 52-week high of $169.58. The firm has a market cap of $6.74 billion, a PE ratio of 86.39 and a beta of 0.99. The firm has a 50-day simple moving average of $134.20 and a 200 day simple moving average of $123.07. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.31 and a quick ratio of 1.31.

Masimo (NASDAQ:MASIGet Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.06. Masimo had a net margin of 4.01% and a return on equity of 13.26%. The company had revenue of $492.80 million during the quarter, compared to analysts’ expectations of $487.70 million. During the same period last year, the company posted $0.87 EPS. Masimo’s revenue was down 12.8% on a year-over-year basis. Sell-side analysts anticipate that Masimo Co. will post 3.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MASI has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, May 8th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $121.00 target price (up from $107.00) on shares of Masimo in a research report on Tuesday, January 30th. StockNews.com raised shares of Masimo from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Piper Sandler raised their target price on shares of Masimo from $117.00 to $126.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 8th. Finally, Wells Fargo & Company raised shares of Masimo from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $117.00 to $160.00 in a research report on Monday, March 25th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $138.71.

Get Our Latest Analysis on Masimo

Insider Activity at Masimo

In other Masimo news, Director Craig B. Reynolds sold 40,000 shares of Masimo stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $136.17, for a total value of $5,446,800.00. Following the completion of the transaction, the director now directly owns 7,406 shares of the company’s stock, valued at $1,008,475.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.70% of the stock is currently owned by corporate insiders.

Masimo Profile

(Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Further Reading

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.